Table 1.

Baseline characteristics for 46 women randomized to placebo or ω-3 fatty acid supplementation arms.

Median (range) or N (%)
TotalPlaceboω-3 fatty acidsComparison between arms
VariableN = 46N = 23N = 23Pa
A) Demographic and risk variables
Age, y53 (40–67)52 (40–63)53 (42–67)0.61
Tyrer-Cuzick 10-yr risk, %8.4 (1.9–31.8)9.0 (3.0–12.7)7.6 (1.9–31.8)0.38
Menopausal Peri11 (24%)6 (26%)5 (22%)1.00
 Post35 (76%)17 (74%)18 (78%)
Genetic test Not tested36 (78%)19 (83%)17 (74%)0.15
 Wildtype6 (13%)1 (4%)5 (22%)
 Del mutation4 (9%)3 (13%)1 (4%)
Prior precancerous No36 (78%)18 (78%)18 (78%)1.00
 Yes10 (22%)5 (22%)5 (22%)
On OC/HRT? No29 (63%)16 (70%)13 (57%)0.54
 Yes17 (37%)7 (30%)10 (43%)
B) Anthropomorphic and body composition variables
Height, cm165 (155–175)163 (155–175)165 (155–175)0.15
Weight, kg84.8 (69.2–115.6)81.3 (69.2–111.2)85.8 (75–115.6)0.081
BMI, kg/m231.0 (27.9–42.4)30.7 (27.9–39.8)31.2 (27.9–42.4)0.28
Waist circumference, cm100 (80–120)101 (80–115)100 (84–120)0.93
Body fat, percent49 (37–55)46 (37–55)49 (42–53)0.028a
FMI, kg/m214.3 (10.1–21.2)13.5 (10.1–20.5)14.7 (11.7–21.2)0.11
  • aMann–Whitney nonparametric test, 2-sided. Similar lack of difference between randomized arms was observed if only the 42 women completing the 6-month intervention and evaluable for biomarkers were analyzed for baseline demographic and risk factors. Exceptions were the marginal statistical significance for body fat percent was lost (P = 0.078).